Rivaroxaban (Xarelto)

inquiry

Cat No.

CEI-0243

Description

Rivaroxaban (Xarelto, BAY 59-7939)can inhibit Factor Xa with IC50 of 0.7 nM.

CAS_No

366789-02-8

Molecular Weight

435.88

Purity

>99%

Storage

2 years at -20 centigrade

Targets

Factor Xa

Molecular Formula

C19H18ClN3O5S

Chemical Name

(S)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide

Solubility

DSMO 87 mg/mL Water

In vitro

Rivaroxaban is an oral, direct inhibitor of Factor Xa (FXa), being developed for the prevention and treatment of arterial and venous thrombosis with a Ki of 0.4 nM. Rivaroxaban exhibits high permeability and polarized transport across Caco-2 cells as a substrate of the P-gp, but exhibits no inhibitory effect on P-gp-mediated drug transport up to concentrations of 100 uM in vitro.

In vivo

Rivaroxaban reduces venous thrombosis in a dose dependent manner (ED50 0.1 mg/kg i.v.) in a rat venous stasis model. Rivaroxaban reduces arterial thrombus formation in an arteriovenous (AV) shunt in rats (ED50 5.0 mg/kg p.o.) and rabbits (ED50 0.6 mg/kg p.o.).

Name:

Email *

Phone:*

Company/Institution:

Country or Region:

Quantity:

Services & Products Interested *

Project Description:

Our Products Cannot Be Used As Medicines Directly For Personal Use.

Products

Online Inquiry